1. Home
  2. TIL vs SWKH Comparison

TIL vs SWKH Comparison

Compare TIL & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • SWKH
  • Stock Information
  • Founded
  • TIL 2018
  • SWKH 1996
  • Country
  • TIL United States
  • SWKH United States
  • Employees
  • TIL N/A
  • SWKH N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • SWKH Diversified Financial Services
  • Sector
  • TIL Health Care
  • SWKH Finance
  • Exchange
  • TIL Nasdaq
  • SWKH Nasdaq
  • Market Cap
  • TIL 218.4M
  • SWKH 210.8M
  • IPO Year
  • TIL 2021
  • SWKH 1999
  • Fundamental
  • Price
  • TIL $26.50
  • SWKH $16.10
  • Analyst Decision
  • TIL Buy
  • SWKH
  • Analyst Count
  • TIL 4
  • SWKH 0
  • Target Price
  • TIL $100.33
  • SWKH N/A
  • AVG Volume (30 Days)
  • TIL 154.7K
  • SWKH 7.1K
  • Earning Date
  • TIL 11-13-2024
  • SWKH 11-14-2024
  • Dividend Yield
  • TIL N/A
  • SWKH N/A
  • EPS Growth
  • TIL N/A
  • SWKH N/A
  • EPS
  • TIL N/A
  • SWKH 0.84
  • Revenue
  • TIL N/A
  • SWKH $24,725,000.00
  • Revenue This Year
  • TIL N/A
  • SWKH N/A
  • Revenue Next Year
  • TIL $2.64
  • SWKH $6.17
  • P/E Ratio
  • TIL N/A
  • SWKH $19.19
  • Revenue Growth
  • TIL N/A
  • SWKH N/A
  • 52 Week Low
  • TIL $6.08
  • SWKH $15.77
  • 52 Week High
  • TIL $92.00
  • SWKH $18.75
  • Technical
  • Relative Strength Index (RSI)
  • TIL 38.29
  • SWKH 37.07
  • Support Level
  • TIL $24.31
  • SWKH $16.17
  • Resistance Level
  • TIL $37.24
  • SWKH $17.10
  • Average True Range (ATR)
  • TIL 4.02
  • SWKH 0.48
  • MACD
  • TIL 0.26
  • SWKH -0.03
  • Stochastic Oscillator
  • TIL 10.85
  • SWKH 15.44

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Share on Social Networks: